Precision Obesity / Metabolic Health

About ReviveMed

ReviveMed is a private, pre-revenue biotech company founded in 2017, commercializing an AI and machine learning platform for metabolomics. Its core technology, developed at MIT, addresses key challenges in metabolite signal detection and annotation, enabling the creation of generative models and virtual patient simulations. The company is initially targeting precision obesity and precision oncology, specifically aiming to predict patient response to cancer immunotherapies and better assess metabolic disease risk beyond traditional metrics.

Therapeutic Areas